![Man ultramarathon runner in the mountains he trains at sunset](https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png)
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Pharmacol. , 09 October 2018
Sec. Experimental Pharmacology and Drug Discovery
Volume 9 - 2018 | https://doi.org/10.3389/fphar.2018.01128
This article is a correction to:
Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR
A Corrigendum on
Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR
by Huang, J., Ren, R., Bao, Y., Guo, J., Xiang, W., Jing, X., et al. (2018). Front. Pharmacol. 9:1016. doi: 10.3389/fphar.2018.01016
In the original article, there was a mistake in Figure 1 as published. The images used for the group of OVX+U were from a different study. The corrected Figure 1 appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
Figure 1. Ulinastatin inhibits bone loss induced by OVX. (A) μ-CT images of the trabecular bone of distal femoral metaphysis from the SHAM, OVX, and OVX + ulinastatin groups. (B) The trabecular structural parameters of the distal femur: trabecular bone volume/tissue volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), and trabecular separation (Tb.Sp). Data are presented as means ± SD. n = 10 and *P < 0.05.
The original article has been updated.
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Keywords: ulinastatin, uPAR, osteoclast, MAPKs, NF-kB, RANKL, osteoporosis
Citation: Huang J, Ren R, Bao Y, Guo J, Xiang W, Jing X, Shi J, Zhang G, Li L, Tian Y, Kang H and Guo F (2018) Corrigendum: Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR. Front. Pharmacol. 9:1128. doi: 10.3389/fphar.2018.01128
Received: 07 September 2018; Accepted: 14 September 2018;
Published: 09 October 2018.
Edited and reviewed by: Wolff Mayer Kirsch, Loma Linda University Medical Center (LLUMC), United States
Copyright © 2018 Huang, Ren, Bao, Guo, Xiang, Jing, Shi, Zhang, Li, Tian, Kang and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hao Kang, a2FuZ2hhbzEwMEB2aXAuc2luYS5jb20=
Feng-jin Guo, Zmd1b0B0amgudGptdS5lZHUuY24=
†These authors have contributed equally to this work
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.